UNSPSC 51101920: Artemisinin

This classification denotes an antiprotozoal agent with the molecular formula C15H22O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9RMU91N5K2, chemically known as 3,12-epoxy-12h-pyranol(4,3-j)-1,2-benzodioxepin-10(3h)-one, octahydro-3,6,9-trimethyl-, (3-alpha,5a-beta,6-beta,8a-beta,9-alpha,12-beta,12ar*)-(+)- but generally known as artemisinin, which bears US NIH Compound Identifier 68827. artemisinin most often comes in base, type a, and type b forms.

UNSPSC 51101920 Artemisinin is a Commodity code nominally describing a specific antimalarial compound, but recent state and local procurement activity under this code shows minimal alignment with the code's abstract scope — the opportunities posted instead reflect broad pharmaceutical procurement spanning naloxone, first-aid medical supplies, generic pharmaceuticals, and OTC products. State and local issuing bodies soliciting under this code include county health departments (Seminole County, Florida), municipal fire departments and purchasing offices (City of Tampa), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The work being bought is pharmaceutical products and medical supplies in volume — from emergency response medications and first-aid consumables for fire rescue operations to generic pharmaceuticals distributed across state and local health facilities through authorized wholesalers.

Recent activity spans Florida, Texas, and Minnesota through cooperative purchasing channels. Seminole County, Florida issued IFB60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually (response due July 26, 2023). The City of Tampa released ITB 26P00145 on March 25, 2026, for 169 line items of medical and first-aid supplies for the Tampa Fire Department Rescue Division, estimated at $700,000, with a 5 percent bid discount set-aside for certified Small Local Business Enterprises (response due March 13, 2026). The Texas HHS Commission posted RFI HHS0017013 on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. MMCAP issued RFP S1070000015802 on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products serving participating state and local facilities in Minnesota and Oregon (response due March 26, 2026). The code shows activity from diverse issuing bodies but limited relevance to artemisinin specifically — pharmaceutical procurement here spans acute-care, emergency response, and chronic disease management rather than antimalarial compound procurement.